Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition

M. Kuttke, E. Sahin, J. Pisoni, S. Percig, A. Vogel, D. Kraemmer, L. Hanzl, J. S. Brunner, H. Paar, K. Soukup, A. Halfmann, A. M. Dohnal, C. W. Steiner, S. Blümi, J. Basilio, B. Hochreiter, M. Salzmann, B. Hoesel, G. Lametschwandtner, R. Eferl, J. A. Schmid, and G. Schabbauer

ABSTRACT
Tumor–host interaction is determined by constant immune surveillance, characterized by tumor infiltration of myeloid and lymphoid cells. A malfunctioning or diverted immune response promotes tumor growth and metastasis. Recent advances had been made by treating of certain tumor types, such as melanoma, with T-cell checkpoint inhibitors. This highlights the importance of understanding the molecular mechanisms underlying the crosstalk between tumors and their environment, in particular myeloid and lymphoid cells. Our aim was to study the contribution of the myeloid PI3K/PTEN-signaling pathway in the regulation of tumor-immune surveillance in murine models of cancer. We made use of conditional PTEN-deficient mice, which exhibit sustained activation of the PI3K-signaling axis in a variety of myeloid cell subsets such as macrophages and dendritic cells (DCs). In colitis-associated colon cancer (CAC), mice deficient in myeloid PTEN showed a markedly higher tumor burden and decreased survival. We attributed this observation to the increased presence of immune-modulatory conventional CD8α+ DCs in the spleen, whereas other relevant myeloid cell subsets were largely unaffected. Notably, we detected enhanced surface expression of PD-L1 and PD-L2 on these DCs. As a consequence, tumoricidal T-cell responses were hampered or redirected. Taken together, our findings indicated an unanticipated role for the PI3K/PTEN-signaling axis in the functional regulation of splenic antigen-presenting cells (APCs). Our data pointed at potential, indirect, tumoricidal effects of subclass-specific PI3K inhibitors, which are currently under clinical investigation for treatment of tumors, via myeloid cell activation.

INTRODUCTION

The PI3K/PTEN-signaling axis is an important pathway in regulating growth, cell cycle, migration and survival of cells. Hyper-activation of PI3K signaling by deletion or deactivation of the counteracting phosphatase, the tumor-suppressor PTEN (phosphatase and tensin homolog located on chromosome 10), was found in various late-stage human cancers.1 So far, the role of this central pathway in the regulation of innate immune cell fate and activity has not been clarified.

We previously showed that deletion of PTEN in myeloid cells results in an anti-inflammatory phenotype, characterized by reduced expression of pro-inflammatory factors.2,3 Accordingly, this anti-inflammatory phenotype (due to PTEN deletion) in macrophages led to a decreased inflammatory response and increased survival in a bacterial infection model.4 Furthermore, livers of myeloid PTEN-deficient mice were protected against ischemia-reperfusion injury (IRI) due to increased production of IL-10,5 and gut homing via CCL25/CCR9 signaling was increased by shRNA knock-down of PTEN.6

The myeloid PI3K/PTEN-signaling pathway further has a role in DC development. Reizis and co-workers showed that deletion of PTEN in mouse haematopoietic cells promoted the development of FMS-like tyrosine kinase 3 ligand (Flt3L)-driven DCs in vitro bone-marrow cultures. In vivo studies showed that DC-specific deletion of PTEN also increased DC numbers, in particular CD8α+ splenic DCs and CD103+ peripheral DCs.
specifically, downstream of PI3K signaling, mTOR mediated Flt3L-induced CD8α+ DC and CD103+ DC development, which could be inhibited by rapamycin.13 Rapamycin affects DC development, maturation and function, since rapamycin-treated DCs reduced T-cell activation and led to anergy (reviewed in reference8). mTOR signaling further favored IL-10 over IL-12 production, which closely resembles the phenotype observed in PTEN-deficient DCs.9,10 A recent publication found an involvement of rapamycin-sensitive mTOR signaling in the induction of IL-10, PD-L1 and PD-L2.11 APCs have increased capacities for antigen-presentation than macrophages. Indeed some subsets are also able to present exogenous and endogenous antigens to T-cells, both via MHCII and MHCI (cross-presentation). The resulting response of T-cells further depends on co-stimulatory molecules (signal 2) and instructing cytokines (signal 3). Signaling via peptide-MHC TCR (signal 1) without co-stimulation (signal 2) results in anergic T-cells and tolerance induction. DCs are directly able to inhibit or even shut down T-cell responses via inhibitory members of the B7-family, enabling and endogenous antigens to T-cells, both via MHCI and MHCII (cross-presentation). The resulting response of T-cells further depends on co-stimulatory molecules (signal 2) and instructing cytokines (signal 3). Signaling via peptide-MHC TCR (signal 1) without co-stimulation (signal 2) results in anergic T-cells and tolerance induction. DCs are directly able to inhibit or even shut down T-cell responses via inhibitory members of the B7-family, enabling DCs to present tumor- or virus-derived antigens via MHCI to CD8α+ T-cells. This is the pathway that enables CD8α+ DCs to present tumor- or virus-derived antigens. Depending on additional signals, presentation of self-antigens might result in cross-priming or cross-tolerance.14

PTEN-deficiency in cells of myeloid origin gives rise to an immune-suppressive phenotype that is advantageous in models of acute infection and inflammation. In an autoimmune animal model resembling human multiple sclerosis, myeloid PTEN-deficiency attenuated disease severity and progression suggesting that innate PI3K/PTEN signaling controls activation and intensity of adaptive immune responses.15 Tumor-immune surveillance (mounting an immunological response against abnormally proliferating self-tissue) might therefore also be similarly affected and thus tumor-cell rejection and elimination by the adaptive immune system impaired. To address this question, we applied two different tumor models (orthotopically implanted B16 melanoma and CAC) in PTENfl/fl LysM cre (myPTEN−/+ ) and WT littermate (myPTEN−/+ ) control mice and found that myeloid PTEN-deficiency results in decreased tumor-immune surveillance caused by immune-checkpoint inhibition.

**Material and methods**

**Animals**

Animals were housed under SPF conditions; all experiments were approved by the Austrian Federal Ministry for Health.
Immunohistochemistry

Paraffin-embedded colons were cut at a thickness of 5 μm and left to dry overnight. Paraffin was removed with Xylene and a series of decreasing percentage alcohol solutions. Antigen retrieval was done using heat-induced antigen retrieval by gentle cooking for 10 min at pH 9.0–adjusted TRIS buffer for CD3, or by applying a solution of 20 μg/mL Proteinase K for 10 min at 37°C for F4/80. Slides were then rinsed, permeabilized with a 0.2% solution of Triton x-100 and blocked with a solution of 10% donkey serum and 1% BSA for 2 h at RT. The same solution was also used as diluent for the primary and secondary antibody. The primary antibody was incubated overnight at 4°C. Slides were then rinsed well and the secondary antibody was incubated for 1 h at RT. The slides were then counterstained with a 5 μg/mL Hoechst solution for 15 min at RT. Finally, they were rinsed thoroughly and mounted with DAKO fluorescent mounting medium. 1x TBS with 0.025% Triton x-100 was used as a diluent for all solutions. Stained sections were scanned with a Nikon A1 confocal laser scanning microscope.

Bioluminescence imaging

Bioluminescence imaging of B16-F10-Ova-Luc melanoma growth was recorded in an IVIS Lumina Series III pre-clinical imaging system (Perkin–Elmer). Before the measurement, mice were kept anesthetized with 2% Furane/O₂. Several images were taken at an exposure of 2–30 sec, depending on tumor size; the maximal photon flux (p/s) after 8–12 min was used for estimation of tumor size.

Single-cell preparations from tissues

Single cells from colons were isolated by first incubating colons with 5 mM EDTA for 2 × 20 min, to gain intestinal epithelial cells (IELs), followed by enzymatic digestion with 10 mg collagenase VIII (Sigma) and 69.6U DNAseI (Worthington) per colon to isolate cells from colon lamina propria (CLP). Cells from spleens were isolated by enzymatic digestion of whole spleens with 30 mg collagenase D (Roche), 300U hyaluronidase (Sigma-Aldrich) and 30 ug DNAseI (Roche) followed by filtering through 70 μm cell strainers and lysis of erythrocytes. Mesenteric lymph nodes were removed and filtered through 70 μm cell strainers to obtain single-cells suspensions. Single cells isolated from these organs were further labeled with CD11c or CD11b antibodies (Miltenyi Biotech) for magnetic cell enrichment according to manufacturer’s protocols.

Flow cytometry

For flow cytometry analysis, single-cell suspensions from colon LP and epithelium, mesenteric lymph nodes and spleen were
stained using the following antibodies: CD45.2-APC-eFluor780 (eBioscience), CD3ε-APC-eFluor780 (eBioscience), CD3-CF594 (BD Biosciences), CD4+.PerCP (BD Biosciences), CD4+.eFluor710 (eBioscience), CD8a-PE (eBioscience), CD8α-Brilliant Violet 510 (BioLegend, Brilliant Violet™ products are trademark of Sirigen Group Ltd.), CD8α-Alexa Fluor 700 (eBioscience, Alexa Fluor® products are trademark of Molecular Probes, Inc.), CD25-PerCP-Cy5.5 (eBioscience), CD69-PECy7 (eBioscience), PD1-AF700 (eBioscience), CD107a-PE (eBioscience), B220-Alexa700(eBioscience), B220- Brilliant Violet 510 (BioLegend), CD11b-APC (eBioscience), CD11c-eFluor450 (eBioscience), NK1.1-PE-Cy7 (eBioscience), NK1.1-APC (eBioscience), GR1-FITC (eBioScience), MHCIIC-FITC (eBioscience), CD274(PD-L1)-PE-Cy7 (eBioscience), CD273(PD-L2)-PerCP-eFluor710 (eBioscience), CD103- Brilliant Violet 510 (Biolegend), 7-AAD (Tonbo), SYTOX (Thermo Fisher Scientific). Flow cytometry acquisition was performed on a LSR Fortessa flow cytometer (BD Biosciences) or a Gallios flow cytometer (Beckman Coulter). Data were analyzed with FlowJo software version 9 (Treestar) or Kaluza (Beckman Coulter). For intracellular cytokine production analysis, splenocytes were isolated and restimulated with anti-CD3/CD28 dynabeads (Life Technologies) and PMA/Ionomycin (Sigma) treatment together with Golgi-Stop (BD Biosciences) for 4 h. The following antibodies were used for cytokine staining: IFNγ-PE (eBioscience), IL-17-PE-Cy7 (eBioscience), IL-2-eFluor 450 (eBioscience), IL-10–AF647 (eBioscience). CFSE proliferation dye was purchased from eBioscience and cells were labeled according to manufacturer’s instructions.

**RT-qPCR**

RNA was isolated from cells and tissues using the mRNeasy Kit (Qiagen) or TriFast (PeqLab) and reverse-transcribed into cDNA using High Capacity cDNA Reverse Transcription Kit (Fermentas) according to manufacturer’s protocols. Expression of mRNA was measured using Quantitect RT-PCR 7,500 system (Applied Biosystems) in a StepOne RT-PCR 7,500 system (Applied Biosystems). Ct-values of target genes were normalized to mHPRT and efficiencies calculated from eBioscience and cells were labeled according to manufacturer’s instructions.

**Whole blood cell analysis**

Blood samples were collected in tubes containing 500 mM EDTA and blood parameters were measured on a VET ABC Hematology Analyzer (Scil Animal Care Company).

**Micro-array analysis**

RNA of splenic CD11c+ cells was isolated using the mRNeasy Kit (Qiagen) and submitted for quality control (Agilent Bioanalyzer RNA 6000 Nano), labeling and measurement on a Mouse Gene 2.0 ST Array (Affymetrix) to the Core Facility Genomics at the Medical University of Vienna; labeling, quality control and array measurement were kindly performed by Markus Jeitler. Array data were normalized by RNA Sketch (Expression Console, Affymetrix) and analyzed by the using one-way between-subject ANOVA (unpaired) with a p value <0.05 defining significance. Sample comparison, hierarchical clustering and pathway enrichment analyses were carried out using Transcriptome Analysis Console software (Affymetrix). Gene Functional Annotation analysis was performed using DAVID Bioinformatics Resources 6.7.[18]

**T-cell proliferation measurement**

To assess T-cell proliferation, cells were cultured ex vivo in the presence of plate-bound anti-CD3e for 3 d. Cells were then labeled with 3H-thymidine (1 μCi/well) and incubated for 20 h. Incorporation of labeled thymidine was measured on a scintillation counter. For the measurement of in vivo T-cell proliferation, CD8+T-cells were isolated from spleens of OT-I transgenic mice, enriched using magnetic isolation (Miltenyi Biotech), CFSE labeled and i.v. transferred in to CAC mice. On the following day, mice were immunized with LPS (10 μg/mouse) and SINFEL (2 μg/mouse), T-cells from spleens and mesenteric lymph nodes were isolated and analyzed by flow cytometry on day 3 after i.v. transfer.

**Statistical analysis**

Data were analyzed for Gaussian distribution using GraphPad Prism 5.0 (GraphPad Software Inc.). Data with Gaussian distribution were checked for statistical significance using Student’s t-test, data sets with unequal variances were analyzed using Student’s t-test with Welch’s correction, data with more than two groups were analyzed with one-way ANOVA, data with more than two groups and different conditions were analyzed using two-way ANOVA.

**Results**

**Myeloid PTEN deficiency increases inflammation-driven colon cancer growth and reduces survival**

We2–4 and others5 have previously shown that the conditional knock-out of PTEN in the myeloid cell lineage results in an increased activation of the PI3K pathway, thereby shifting the functional phenotype toward an “alternatively-activated” or “M2-like” state. Most strikingly, pro-inflammatory molecules such as TNFα, IL6 and KC/Gro1 are decreased in myeloid PTEN-deficient mice. This is accompanied by an increase in IL-10, which protects from damaging effects caused by acute inflammation or infection. This acute protective and anti-inflammatory phenotype might become detrimental during chronic inflammation and tumor development.
To address the question of whether this shifted phenotype in the myeloid compartment might have an influence on tumor development, we induced (CAC, Fig. 1A) chemically in PTEN<sup>fl/fl</sup> LysM cre (myPTEN<sup>−/−</sup>) mice by AOM/DSS treatment and did a software-assisted<sup>15</sup> analysis of H&E stained histological sections of colon swiss rolls for tumor development. Myeloid PTEN<sup>−/−</sup> mice showed an increase in tumor incidence (assessed by tumor number per mouse and cm<sup>2</sup>; colon) and progression (assessed by tumor area per colon area) (Fig. 1B). Weight loss during the AOM/DSS treatment period (Fig. 1C) and changes in colon length (Fig. 1D) were similar in myeloid PTEN-deficient mice and littermate controls suggesting that besides an increase in tumor development, AOM/DSS-induced formation of CAC (including inflammation and the course of disease) was similar in both genotypes. In a model of acute colitis, weight loss was not significantly different between myeloid PTEN-deficient and littermate-control mice (Fig. S1B). Male myPTEN<sup>−/−</sup> mice showed a significantly reduced survival rate during the development of CAC (Fig. 1E); survival in female mice was not significantly altered (Fig. S1A). To rule out any influence of differences in the composition of the microbiome between genotypes, PTEN<sup>fl/fl</sup> LysM cre and PTEN<sup>df/df</sup> mice were co-housed. Blood cell counts did not show significant differences when we compared myeloid PTEN-deficient animals to wild types, although myPTEN<sup>−/−</sup> mice produced more granulocytes at the expense of lymphocytes after CAC development compared to untreated control KOs, and the ratio of granulocytes to lymphocytes was also significantly higher than in tumor-bearing WT mice (Fig. S1C). Platelet counts were decreased in CAC mice and MPV was increased—regardless of genotype—most probably due to the DSS treatment during which mice suffer from bleeding events. Hence, myPTEN<sup>+/+</sup> and myPTEN<sup>−/−</sup> mice exhibited comparable colitis-associated inflammation leading to the development of colon cancer but the PTEN-deficiency in the myeloid cell compartment significantly attenuated tumor-immune surveillance.

Myeloid PTEN-deficient mice show enhanced growth of B16-F10 melanoma

To address the question of whether the observed enhanced tumor growth upon AOM/DSS treatment in myeloid-PTEN deficient mice might be restricted to endogenously grown tumors and to rule out that only tumor initiation is affected, we injected myPTEN<sup>−/−</sup> and myPTEN<sup>+/+</sup> with B16-F10-Ova-Luc melanoma cells. These cells were previously transduced with a lentiviral construct encoding a red-shifted firefly luciferase to allow for a more precise estimate of tumor growth via measurement of bioluminescence. PTEN<sup>df/df</sup> LysM cre mice showed an increased tumor growth in this orthotopically-implanted tumor model over 10 d (Figs. 2A and B). We observed a rejection of tumors in some mice, leading to an almost complete elimination of the tumors 10 d after subcutaneous injection (Fig. 2B).
This was usually not the case with conventional B16-F10-melanomas, but a decrease in \textit{in vivo} growth rate was already observed in ovalbumin-expressing B16-F10 cells (compared to an ova negative-cell line, Fig. S6B), indicating an increase in immunogenicity. Myeloid PTEN-deficient and control mice did not show any significant difference in weight change (Fig. 2C) or blood parameters (Fig. S2A), with the exception of the lymphocyte to granulocyte ratio. Similar to the changes observed in the CAC model (Fig. S1C), this ratio was decreased.

The increase in tumor load in the B16 melanoma model in myPTEN\textsuperscript{−/−} mice indicated that, independent of tumor origin (endogenously grown or orthotopically implanted), myeloid PTEN-deficiency reduced tumor rejection.

**Myeloid PTEN deficiency increases immune-regulatory CD8α\textsuperscript{+} DCs**

Analysis of flow cytometry data of myeloid cell populations from PTEN\textsuperscript{fl/fl} LysM cre and cre-negative animals revealed an increase in CD11c\textsuperscript{+} cells in the spleens of myPTEN\textsuperscript{−/−} mice (Figs. 3A and B). Splenic CD11b\textsuperscript{−} and CD11c\textsuperscript{+} myeloid cells were not significantly changed in numbers between genotypes (Fig. 3B and data not shown). Within the CD11c\textsuperscript{+} subset, we found CD8α\textsuperscript{+} CD11c\textsuperscript{+} cells significantly increased in myPTEN\textsuperscript{−/−} animals (Figs. 3A and B). The corresponding DCs in the gut (CD103\textsuperscript{+}DCs) were not altered in numbers in PTEN-deficient animals compared to wild types (Fig. 3B). Within the DC compartment in the spleen, myPTEN\textsuperscript{−/−} mice showed a significant increase in professional APCs (CD11c\textsuperscript{+}MHCII\textsuperscript{+}) expressing the immune-checkpoint molecules PD-L1 and PD-L2 (Figs. 3C and D). Both of these inhibitory ligands were shown to bind to PD-1 on T-cells and inhibit proliferation and cytokine production.\textsuperscript{19} CD11c\textsuperscript{+} CD8α\textsuperscript{+} DCs in the spleen that were increased in myPTEN\textsuperscript{−/−} mice also expressed the immune checkpoint-inhibiting ligands PD-L1 and PD-L2 and this finding was independent of genotype (Fig. 3E). There was no significant difference between the number of CD11c\textsuperscript{+} CD11b\textsuperscript{+} cells expressing PD-L1 versus PD-L2. CD11b\textsuperscript{+}CD11c\textsuperscript{+} cells expressing PD-L1 or PD-L2 did not significantly differ in number, but their numbers were lower than those of CD11b\textsuperscript{−} (CD11c\textsuperscript{−}) DCs, although the difference was less pronounced when considering PD-L2 expressing cells (Fig. 3D and Fig. S3A). The increase in CD11c\textsuperscript{+} dendritic cells in the spleen was also observed in healthy animals, as was the increase in the CD11c\textsuperscript{+} CD8α\textsuperscript{+} subset, and could therefore be attributed to the PTEN knockout in dendritic cells,\textsuperscript{7} which are also targeted by the LysM promoter.\textsuperscript{20} Nevertheless, CD11c\textsuperscript{+} and CD11c\textsuperscript{+} CD8α\textsuperscript{+} increased in numbers after CAC induction (0.9% to 2% CD11c\textsuperscript{+} in myPTEN\textsuperscript{−/−} and 1.7% to 4.5% CD11c\textsuperscript{+} cells in spleen-SPL, colon lamina propria-CLP and colon epithelium-CEP), values are expressed as % of live cells, n = 4–6, *p < 0.05, **p < 0.01. (E) Splenic CD11c\textsuperscript{+} MHCII\textsuperscript{+} APCs co-express CD8α and PDL-1 or PDL-2, respectively. (F) Myeloid subsets and immune checkpoint inhibitors in naive healthy mice, gating as in (A) or (C), respectively, values are expressed as % of live cells, n = 4–5, *p < 0.05.
in myPTEN<sup>−/−</sup> and 0.1% to 0.4% CD11c<sup>−</sup>CD8α<sup>+</sup> in myPTEN<sup>+/+</sup> and 0.8% to 1.9% CD11c<sup>−</sup>CD8α<sup>+</sup> in myPTEN<sup>−/−</sup>, respectively. Figs. 3B and F). Healthy control mice of both genotypes did not show any significant difference in numbers of PD-L1 or PD-L2 expressing CD11c<sup>−</sup>MHCII<sup>+</sup> APCs in the spleen (Fig. 3F), but after CAC development their numbers increased about 4-fold (0.9% to 4.0% PD-L1<sup>−</sup>APCs and 0.4% to 1.9% PD-L2<sup>−</sup>APCs) in myPTEN<sup>−/−</sup> mice and remained almost unchanged in myPTEN<sup>+/+</sup> animals (Figs. 3D and F). We further found a non-significant trend toward an increase in MDSCs (CD11b<sup>−</sup> GR1<sup>+</sup>) in spleen, colon lamina propria and colon epithelium (Fig. S3B) of myPTEN<sup>−/−</sup> mice. MDSCs were shown to be increased in the spleen and bone marrow of C57BL/6 mice by DSS treatment.21 In the B16 melanoma model, myeloid PTEN-deficient mice exhibited an increase in splenic CD11b<sup>−</sup>, CD11b<sup>+</sup>CD11c<sup>+</sup> and CD11c<sup>+</sup> cells (Fig. S2B). The highest increase in cell numbers between myPTEN<sup>+/+</sup> and myPTEN<sup>−/−</sup> animals was observed in the CD11c<sup>−</sup>CD8α<sup>+</sup> compartment. Surprisingly, CD11b<sup>−</sup>CD11c<sup>+</sup> cells expressing either PD-L1 or PD-L2, did not significantly differ in numbers, although there seemed to be a trend toward an increase of PD-L1 or PD-L2 expressing CD11c<sup>−</sup> cells in myPTEN<sup>−/−</sup> mice that didn’t reject the tumor, which was completely absent in myPTEN<sup>+/+</sup> mice.

Taken together, myeloid PTEN-deficient mice showed increased numbers of CD11c<sup>−</sup> and more specifically CD11c<sup>−</sup>CD8α<sup>+</sup> cells in the spleen, which also express either PD-L1 or PD-L2, after CAC development. Both of these inhibitory surface proteins become upregulated during tumor progression and PD-L1 or PD-L2 expressing APCs are even more abundant in myPTEN<sup>−/−</sup> mice, indicating that immune-checkpoint inhibition by PD-Ls attenuated tumor-immune surveillance in myeloid PTEN deficiency.

### Gene-expression profile of splenic PTEN-deficient DCs of CAC mice

Since deletion of PTEN in myeloid cells resulted in an increase in immune-suppressive myeloid cells, we were interested in the genetic basis that accounted for the observed tumor-promoting phenotype of professional APCs (Fig. 4A). mRNA array-expression analysis of enriched CD11c<sup>−</sup> cells revealed an increased expression of Batf3 and Bcl6 as well as a concomitant decrease of Irf4, Runx3, Relb and Pu.1 (also known as Spib), in myPTEN<sup>−/−</sup> compared to myPTEN<sup>+/+</sup> mice. The relative changes in the levels of these transcription factors (TF) resemble their changes during

---

**Figure 4. Transcriptome analysis of enriched splenic CD11c<sup>−</sup> cells.** (A) Heatmap of differentially expressed genes considering a p value of <0.05 as significantly changed. (B) Selection of most significantly changed Kegg pathways containing differentially expressed genes in splenic CD11c<sup>−</sup> cells from myPTEN<sup>−/−</sup> and myPTEN<sup>+/+</sup> mice; list is sorted according to p value. (C) Fold changes of transcription factors involved in DC development and function. (D) Fold changes of selected genes known to be differentially regulated between myPTEN<sup>−/−</sup> and myPTEN<sup>+/+</sup> in CD11b<sup>−</sup> and CD11c<sup>−</sup> cells.
CD8α⁺ DC development (Fig. 4C). The most highly upregulated TF was Batf3, which has been shown to be indispensable for CD8α⁺ DC development. This present finding clearly showed that DCs isolated from myPTEN−/− were predominantly CD8α⁺ DCs. Next, we were interested in relevant pathways for DC function that were affected most significantly by deletion of PTEN. Therefore, we analyzed all genes with a log2-expression value of more than four in at least one sample, so as to focus only on highly expressed genes in CD11c⁺ cells. Furthermore, we concentrated on genes that were at least 1.5-fold differentially regulated and analyzed the pathways containing these genes. Using the KEGG collection, we found 14 pathways affected by upregulated genes and 26 pathways influenced by downregulated genes (Fig. 4B and Fig. S4A). The expression of some genes known to be affected by myeloid PTEN-deletion was further validated by qPCR and their fold changes were compared to the mRNA array data. All analyzed genes showed similar trends for up or downregulation (Fig. 4D). We further compared the qPCR expression data from isolated CD11c⁺ cells with isolated CD11b⁺ cells. Different expression of IL-10, Fizz-1 and Stab-1 clearly showed that these two cell populations were distinct, with different transcriptional and phenotypical properties, although both cell populations were deficient for PTEN (Fig. 4D). These findings further supported the notion that CD8α⁺DCs from myPTEN−/− mice were immature and not efficient in T-cell activation.

**T-cells from CAC myPTEN−/− mice are rendered hypo-responsive**

Considering the observed increase in PD-L⁺CD8α⁺ DCs in myPTEN−/− animals, we were interested in the functional phenotype of T-cells in these mice. First, relative numbers of CD4⁺ T-helper (Th) and CD8⁺ cytotoxic T-cells (CTL) were analyzed by flow cytometry. Except for an increase in CD8⁺ CTLs in the spleens of myPTEN−/−, there was no significant difference in the numbers of B-, T- or NK-cells, between genotypes in any analyzed organ (Fig. 5A and data not shown). All cell populations in mesenteric lymph nodes and spleen were decreased in CAC mice compared to healthy controls, except splenic B-cells (Fig. 5B and data not shown). Quite strikingly, cell populations in the colon (lamina propria and epithelium) were almost unchanged between CAC

---

**Figure 5.** Myeloid PTEN deficiency induces hypo-responsiveness in T-cells. (A) Quantification of flow cytometry analysis of (live, CD45⁺ CD3⁺) CD4⁺ T-helper cells and CD8⁺ CTLs in spleen (SPL), colon lamina propria (CLP) and colon epithelium (CEP) of CAC mice, values are expressed as % of live cells, n = 4–6, *p < 0.05; (B) quantification as in (A) of healthy animals, values are expressed as % of live cells, n = 4–5; (C) proliferation of total splenocytes of myPTEN+/+ and myPTEN−/− mice after ex vivo culture for 3 d in the presence of activating anti-CD3e measured by the incorporation of radioactive 3H-thymidine, n = 8, *p < 0.05; (D) Proliferation of CFSE-labeled OT-I T-cells 3 d after i.v. transfer into myPTEN+/+ and myPTEN−/− CAC mice. Mice were immunized with LPS/Ova one day after i.v. transfer, proliferation was assessed by CFSE dilution and is shown as % OT-I T-cells in SPL and MLN, % proliferating OT-I T-cells and MFI of CFSE, n = 2–5, values were measured in triplicates, *p < 0.01, **p < 0.001; (E) representative CD3-IHC and (F) F4/80 staining of paraffin-embedded sections of colon swiss rolls from myPTEN+/+ and myPTEN−/− CAC mice and quantification of positive stained areas per tumor area, values are expressed as % of tumor area, n = 15–17, *p < 0.01, **p < 0.001.
and healthy animals, with the exception of CD4+ T-helper cells in colonic epithelium that were increased in CAC mice (1.3% to 2% in myPTEN+/+ and 1.5% to 3% in myPTEN−/−, Figs. 5A and B), which was more pronounced in myPTEN−/− mice. This finding could also be confirmed by IHC staining for CD3 on sections from colon swiss rolls of CAC mice, showing that myPTEN−/− mice disclosed higher numbers of infiltrating T-cells per tumor (Fig. 5E).

Relative numbers of CD4+ and CD8+ T-cells in the lamina propria and epithelium of the colon further showed that the separation of both compartments was as anticipated, since CD4+ T-cells are primarily found in the lamina propria and CD8+ T-cells in the colon epithelium.23 The proliferative capacity of splenic T-cells from CAC myPTEN−/− animals was reduced compared to myPTEN+/+ when total splenocytes were cultured ex vivo for 3 d in the presence of activating anti-CD3ε (Fig. 5C). Consistently, analysis of flow cytometry data of intracellularly stained splenocytes revealed an increase in IL-10+ in CD8+ CTLs (Fig. S5B and Fig. S5C). In vivo data obtained from flow cytometry analysis of CFSE-labeled i.v. transferred OT-1 CD8+ T-cells showed a reduction in percentage of OT-1 T-cells as well as percentage of proliferating OT-1 T-cells in spleens and mesenteric lymph nodes of tumor-bearing myPTEN−/− mice. This impairment of CD8+ T-cell proliferation was further substantiated by a higher MFI of CFSE in myPTEN−/− mice (Fig. 5D). Additionally, a higher infiltration of F4/80 monocytes was found in tumors of myPTEN−/− compared to myPTEN+/+ mice (Fig. 5F). Some of these cells were also positive for Arg1, while others were negative, regardless of genotype. Flow-cytometry analysis revealed an increase of CD80 and CD86 positive and negative F4/80 monocytes in myeloid PTEN-deficient mice. iNOS mRNA expression in cell suspensions of colon lamina propria and epithelium showed a decrease in cell from myPTEN−/− mice compared to WTs (data not shown). These findings indicated that the increased population of F4/80 monocytes in myPTEN−/− mice did not represent pro-inflammatory infiltrates.

**T-cells from B16 myPTEN−/− mice show reduced killing in vitro**

Analysis of CD4+ and CD8+ T-cells from myPTEN+/+ and myPTEN−/− mice injected with B16-Ova-Luc melanoma cells showed a slight, although not significant, reduction in CD4+ T-helper cells and CD8+ CTLs in spleens of myeloid PTEN-deficient mice (Fig. 6A). Furthermore, a higher percentage of splenic CD4+ T-cells expressed CD25 (Fig. 6B) and a higher percentage of CD25+CD4+ T-cells from myPTEN−/− mice were negative for the activation marker CD69 (Fig. 6B). In the CD8+ T-cell subset, we found that the percentage of activated PD-1+ CD8+ T-cells tended to be reduced in myPTEN−/− mice compared to WT controls after B16 inoculation. PD-1 is usually upregulated upon T-cell activation, enabling the negative feedback loop through inhibitory PD-L1 or PD-L2 binding.12 CD107a is a marker for degranulation, as it is located in the membrane near sites of cytolytic granule release after membrane fusion.24,25 CD107a was found to be only slightly, but not significantly, reduced in myPTEN−/− mice (Fig. 6B). These results indicated that CD8+ T-cells were not sufficiently primed and activated for an appropriate antitumor response. To determine whether the observed lack of T-cell activation marker expression also had biological significance, we tested LPS-activated and Ova peptide-primed splenocytes in an in vitro assay for their cytolytic activity toward B16 Ova-melanoma cells (Fig. 6C). While activated splenocytes from myPTEN+/+ led to a significant reduction in B16-Ova-Luc melanoma cells in vitro, myPTEN−/− splenocytes did not. These results suggest that PTEN-deficient dendritic cells did not efficiently prime T-cells, which resulted in decreased elimination of tumor cells in vitro.

![Figure 6](image_url)  
*Figure 6. Myeloid PTEN deficiency induces regulatory T-cells. (A) Quantification of flow cytometry analysis of (live, CD45+ CD3+) CD4+ T-helper and CD8+ CTLs in the spleens of myPTEN+/+ and myPTEN−/− mice 10 d after s.c. B16 melanoma injection, values are expressed as % of live cells, n = 4–7; (B) Quantification of flow cytometry analysis of activation markers PD-1, CD25, CD69 and CD107a in CD4+ T-helper and CD8+ CTLs in the spleens of myPTEN+/+ and myPTEN−/− mice 10 d after s.c. B16 melanoma injection, values are expressed as % of CD4+ or CD8+, respectively, n = 8–14, *p < 0.05, **p < 0.01; (C) in vitro killing of B16-Ova-Luc cells was assayed by measurement of remaining luciferase activity specific for transduced melanoma cells after co-culture for 1 h with LPS/SINIFIXL-primed splenocytes from B16-injected myPTEN+/+ or myPTEN−/− mice as in (A) and (B), respectively, values represent arbitrary luminescence values; n = 2–7, *p < 0.05, **p < 0.01.*
Discussion

The PI3K-signaling pathway induces anti-inflammatory reactions in cells of myeloid origin. It is counter-regulated by PTEN, a lipid and protein phosphatase that acts at the plasma membrane as well as in the nucleus. The precise role of this central pathway in the regulation of myeloid-cell development and function is not fully understood. We previously showed that the activation of the myeloid PI3K signaling pathway leads to a shift toward increased production of anti-inflammatory cytokines. Furthermore, we also showed that the PI3K pathway upregulates the enzyme Arginase-1 in macrophages, which is secreted and exerts autocrine and paracrine immune-suppressing effects. One of those effects is the suppression of effector T-cell responses resulting in amelioration of experimental autoimmune encephalitis as well as anti-inflammatory arthritis in myeloid PTEN-deficient mice. In contrast, the opposite effect was observed in lymphocytes. Here PTEN-deficiency led to hyper-proliferation in affected T-cells, autoimmunity (reviewed in reference), reduced germinal center formation and impaired immunoglobulin class switching in B-cells. Additional findings in innate immune cells suggest that inhibition or deletion of positive integrators in the PI3K-Akt-mTOR pathway in these cells has immune-stimulatory effects and the inhibition or deletion of negative regulators has immune-inhibitory effects (reviewed in reference). In some cases, the effect of deletion of a signaling member depends on the cell type (TSC1-deletion in macrophages or DCs) or the affected isoform (Akt1- or Akt2-deficiency in macrophages). Suppression of innate and adaptive immune responses, which might be beneficial for limiting tissue destruction and prolonging overall survival in models of acute infection and inflammation, might be detrimental during tumor development. To address the question of whether an anti-inflammatory phenotype exerted by cells of the innate immune system has an influence in cancer development and progression, we used two different tumor models in PTEN knockout LysM cre (myPTEN) mice: the endogenous CAC model and the orthotopically implanted B16-melanoma model. CAC myPTEN mice showed an increase in tumor incidence as well as in tumor progression. Colon inflammation was similar between myPTEN and myPTEN mice, as we could not find any differences in weight loss or colon length. Furthermore, the weight change was also similar in an acute model of colitis. Analysis of blood parameters showed no differences between the genotypes with the exception of the ratio of lymphocytes to granulocytes, which was decreased in myPTEN mice in the CAC model compared to healthy controls. Myeloid PTEN-deficient mice showed increased mortality, which unfortunately precluded the analyses of severely affected mice. Surprisingly, this effect was not seen in female mice, indicating an impact of sex on the development of CAC in this protocol, probably due to increased stress in cages containing male animals. To avoid any influence of the microbiome, which clearly has an impact on the development and course of inflammation associated diseases, experiments with myPTEN and myPTEN mice were performed in a littermate-controlled and co-housed way. Taken together, this indicated that the pathologic changes observed in the myPTEN could be attributed to malfunctioning tumor immune-surveillance mechanisms. Indeed, in the second tumor model, where B16 melanoma cells were subcutaneously injected, myPTEN mice also showed an increase in tumor load. This tumor model differed from CAC by an important parameter, namely immunogenicity. Due to two additional neo-antigens—chicken ovalbumin and firefly luciferase—the B16-melanoma cell line we used seemed to elicit an immune response, which led to increased rejection of tumors. Nevertheless, the average tumor load was higher in myeloid PTEN-deficient animals compared to controls. As observed in the CAC model, the ratio of lymphocytes to granulocytes in the B16 model was also decreased in myPTEN mice, indicating that due to PTEN deficiency, hematopoiesis favored innate cell production to lymphocytes. To investigate the dysregulated tumor-immune surveillance in greater detail, we analyzed various innate and adaptive cell subsets. We found splenic CD11c cells as well as CD11c+CD8α+ cells to be increased in myPTEN animals in the CAC as well as in the B16 melanoma model. This finding was independent of disease status, as healthy control animals also showed an increase in this specific innate cell subset. This increase was observed just in CD11c+ cells but not in CD11c- cells, probably due to a higher dependence on a single cytokine (namely Flt3L) which is indispensable for DC development and requires downstream signaling through the PI3K-Akt-mTOR axis. CD8α+ DCs are professional APCs in the spleen capable of cross-presenting exogenous antigens to CD8+ cytotoxic T-cells, thereby activating or preventing T-cell-mediated responses in a context-dependent manner (cross-priming vs. cross-tolerance). This cell population was shown to be more efficient at phagocytosis than CD8α- cells and at inducing regulatory T-cells (Tregs). An increase in CD11c+CD8α+ cells in myeloid PTEN-deficient animals has already been shown. Although the CD11c-cre mouse was used in this study, the LysM-cre mouse also targeted splenic APC, as shown by Gwendalyn Randolph’s group and others. Development of splenic CD8α+DCs depends on the hematopoietin Flt3L, which acts on its receptor, Flt3, to activate downstream signaling via PI3K. In vitro development of CD8α+DCs was further shown to be abrogated by rapamycin treatment, indicating that signaling is mTORC-dependent, which is downstream of PI3K. We were interested in the immune regulatory properties of APCs in the spleen. Since recent data showed regulation of the immune inhibitory ligand PD-L1 by signaling downstream of PI3K, we analyzed the expression of PD-1 ligands, PD-L1 and PD-L2, on splenic APCs that were dependent on PTEN. PD-L1 and PD-L2-expressing professional APCs (CD11c+MHCI) were strongly and significantly increased in myPTEN mice compared to myPTEN littermates. Some myeloid cells expressing PD-L1 or PD-L2 were also positive for CD11b. When we further analyzed the expression of these inhibitory ligands on CD8α+DCs, we found that these cells expressed PD-L1 and PD-L2. Both of these inhibitory ligands were shown to bind PD-1 on T-cells and inhibit proliferation and cytokine production at low antigen concentrations when CD28-mediated co-stimulation was insufficient. Binding of PD-1 to PD-1 induced cell cycle arrest in T-cells and phosphorylation of SHP-2. Selective PD-L1 upregulation was recently shown to be dependent on HIF1α expression and binding to HRE sequences in the PD-L1 promotor region in a MDSC cell line. An overall increase in splenic CD8α+DCs expressing the
inhibitory ligands PD-L1 and PD-L2 therefore indicates an increase in self-tolerance, resulting in attenuation of tumor-immune surveillance in the CAC model. In the B16 melanoma model, we did not observe an increase in PD-L1 or PD-L2 expressing myeloid cells, but an increase of PD-L1 or PD-L2 expressing cells was seen in myPTEN−/− mice, which did not reject tumors. This led us to suggest a correlation between lack of tumor rejection and higher levels of PD-L expression. This tendency of increased PD-L-expressing DCs was only seen in myPTEN−/− mice but not in myPTEN+/− animals.

The relative increase in CD8α+ DCs was further validated at the transcriptional level. Analysis of mRNA-array data revealed that transcription factors important for CD8α+ DC development and function were upregulated in CD11c+ cells from myPTEN−/− mice. The most highly upregulated TF in myPTEN−/− cells was Batf3 that specifically drives CD8α+ DC development.22 Pathway enrichment analysis showed an increase in genes involved in PPARγ signaling, glycerolipid metabolism and cell adhesion. Furthermore FC-γ receptors 1 (high affinity) and 4 (low affinity), complement components, MMP9 and IL-10, were all upregulated thereby affecting pathways involved in systemic lupus erythematosus, asthma, prion diseases and prostate-cancer development. Pathways affected by downregulated genes mostly contained the co-stimulatory molecules CD86 and CD80 as well as the DC activating molecule CD40, ICOS-ligand and Fas. Most interestingly, IL-12b (IL12p40) representing the shared binding partner of IL-12a and b2 molecules CD40, ICOS-ligand and Fas. Most interestingly, IL-12b was more pronounced in myPTEN−/− than in myPTEN+/− mice, which was also seen in IHC staining for CD3 of colon swiss rolls. Analysis of T-cells in an ex vivo culture of whole splenocytes in the presence of activating anti-CD3e antibody revealed a decreased proliferative potential in T-cells from myPTEN−/− mice, indicating that inhibitory dendritic cells present in the spleen indeed block T-cell proliferation. This finding coincided with an increase in IL-10+ CD8+ splenic T-cells in myPTEN−/− mice. Flow cytometric analysis of intracellular T-helper cytokines revealed a slight increase in IL-10+ and IFNγ+ CD4+ T-helper cells in myPTEN−/− animals. The increase of splenic CD8+ T-cells in myPTEN−/− mice could be due to increased proliferation or a block in homing to other organs, but CD8+ CTLs were not reduced in MLN, CLP or CEP of myPTEN−/− animals, indicating that the latter was not the case. Nevertheless, CD8+ T-cells showed a slight, but not significant increase in IL-2 production as well as a trend toward downregulation of the gut-homing receptors CCR9 and α4β7-integrin (data not shown). The observed increase in CD8α+ DCs in the spleens of myPTEN−/− mice would also explain the increase of splenic CD8+ T-cells and IFNγ+ CD4+ T-cells as especially CD8α+ DCs produce high levels of bioactive IL-12p70, which induces Th1 and CTL responses after CpG detection via TLRs.40 However, we did not find any difference in the ability to produce IL-12p40 ex vivo upon CpG stimulation between myPTEN−/− mice and their corresponding controls (data not shown). In an in vivo approach, we transferred ovalbumin-specific CD8+ T-cells into CAC mice and immunized them on the following day. Flow cytometry analysis showed an impairment of T-cell proliferation in myPTEN−/− animals, indicating that DCs capable of cross-presentation inhibit CD8+ T-cell activation. Taken together, these findings pointed toward a blockade of CD8+ CTL activation by engagement of PD-L1 and PD-L2 on CD8α+ DCs. This would consequently cause a higher tumor burden, as deficiencies in development or function of CTLs or Th1-cells results in increased cancer development and mice with combined immunodeficiencies in T- and NK-cells are shown to be more susceptible to cancer development.47

In the B16 melanoma model, myPTEN−/− mice showed slightly reduced levels of T-cells in the spleen. Furthermore, a higher percentage of CD4+ T-helper cells expressed CD25, which is usually considered a marker for Tregs.48 The percentage of CD25+CD69+ cells was also increased in CD4+ T-helper cells of myPTEN−/−. CD69 is a C-type lectin usually upregulated in T- and NK-cells immediately after activation.49-51 CD69+ CD4+ T-cells were shown to exhibit defects in homing to the bone marrow, thereby providing less help to B-cells for plasma-cell differentiation.52 Expression of CD69—at least in vitro—is dependent on antigen exposure.51 Therefore, an increase in CD4+ CD25+ CD69+ in myPTEN−/− animals indicated that these T-helper cells lacked activation, were still naive and might even have a regulatory phenotype.
As a secondary lymphoid organ, the spleen serves primarily as a filter for the blood by removing aged erythrocytes and recycling their hemoglobin, as well as removing opsonized bacteria and generating immune responses. It is also a reservoir for blood and monocytes in case of injury and harbors B- and T-cells. Enlargements of the spleen are observed in leukemia and cancer patients as well as in various infectious and congenital diseases. In early mouse and rat models, splenectomy increased cancer risk in various settings, indicating that the spleen has a protective function during tumor development.\(^\text{55}\) A recent follow-up study of 8,149 veterans who underwent splenectomy for up to 27 y found a 1.51-fold increased risk for developing cancer, with a 1.33-fold increased risk for any cancer, and with a 1.33-fold increased risk for developing colon cancer. Further, splenectomized patients showed an increased risk for any leukemia. Further, splenectomy increased cancer risk in various settings, indicating that the spleen has a protective function during tumor development.\(^\text{55}\)

In conclusion we could show for the first time that genetic deletion of PTEN in myeloid cells specifically increased splenic CD8α dendritic cells, which upregulated the immune checkpoint inhibitors PD-L1 and PD-L2 thereby attenuating T-cell mediated tumor-immune surveillance. Our study indicated that PI3K inhibitors, which are currently being tested for cancer treatment, might have further beneficial immune-modulating effects beyond tumor-cell targeting.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Dr. Aner Gurvitz and Dr. Ron Sterling for a careful and thorough review of the manuscript.

**Funding**

This study was funded by the Austrian Science Fund projects P24802 (to GS) and SFB-F54 (to GS and JS).

**References**

1. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7; PMID:12104018; http://dx.doi.org/10.1126/science.296.5573.1655
2. Luyendyk JP, Schabbauer GA, Tencati M, Holscher T, Pawlinski R, Mackman N. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor expression in monocytes/macrophages. J Immunol 2008; 180:2126; PMID:18322234; http://dx.doi.org/10.4049/jimmunol.180.6.4218
3. Gunzl P, Bauer K, Hainzl E, Matt U, Dillinger B, Mahb B, Knapp S, Binder BR, Schabbauer G. Anti-inflammatory properties of the PI3K pathway are mediated by IL-10/DUSP regulation. J Immunol 2010; 88:1259-69; PMID:20884649; http://dx.doi.org/10.1189/jib.0110001
4. Schabbauer G, Matt U, Gunzl P, Warszawska J, Furtner T, Hainzl E, Elbahn I, Mesteri I, Doninger B, Binder BR et al. Myeloid PTEN promotes inflammation but impairs bactericidal activities during murine pneumococcal pneumonia. J Immunol 2010; 185:468-76; PMID:20505137; http://dx.doi.org/10.4049/jimmunol.0902221
5. Yue S, Rao J, Zhu J, Busuttil RW, Kupiec-Weglinski JW, Lu L, Wang X, Zhai Y. Myeloid PTEN deficiency protects livers from ischemia reperfusion injury by facilitating M2 macrophage differentiation. J Immunol 2014; 192:5343-53; PMID:24771857; http://dx.doi.org/10.4049/jimmunol.1400280
6. Miething C, Scuoppo C, Bosbach B, Appelmann I, Nakitandwe J, Ma J, Wu G, Lintault L, Auer M, Premur P et al. PTEN action in leukemia dictated by the tissue microenvironment. Nature 2014; 510:402-6; PMID:24805236; http://dx.doi.org/10.1038/nature13239
7. Sathaligawala T, O’Gorman WE, Greter M, Bognovic M, Konjufca V, Hov ZE, Nolan GP, Miller MJ, Merad M, Reizis B. Mammalian target of rapamycin controls dendritic cell development downstream of PI3K ligand signaling. Immunity 2010; 33:597-606; PMID:20933441; http://dx.doi.org/10.1016/j.immuni.2010.09.012
8. Wang Y, Chi H. mTOR Signaling and Dendritic Cell Biology. J Immunol Clin Res 2014.
9. Weichhart T, Costantino G, Pogilitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolke T, Stulnig TM, Horl WH, Hengstschlager M et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008; 29:565-77; PMID:18848473; http://dx.doi.org/10.4049/jimmunol.2008.08.012
10. Sahin E, Brunner JS, Kral JB, Kuttke M, Hanzl L, Datler H, Paar H, Neuwinger N, Saferding V, Zinser E et al. Loss of Phosphatase and Tensin Homolog in APCs Impedes Th17-Mediated Autoimmune Encephalomyelitis. J Immunol 2015; PMID:26246144; http://dx.doi.org/10.4049/jimmunol.1402511
11. Rosborough BR, Raich-Rex De GM, Matta BM, Lee K, Gan B, DePinho RA, Hackstein H, Boothby M, Turnquist HR, Thomson AW. Murine dendritic cell ramapycin-resistant and raptor-independent mTOR controls IL-10, B7-H1 and regulatory T-cell induction. Blood 2013; 121 (18):3619-30; PMID:23444404; http://dx.doi.org/10.1182/blood-2012-08-448290
12. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A 2003; 100:5336-41; PMID:12697896; http://dx.doi.org/10.1073/pnas.0931259100
13. Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P; Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014; 211:781-90; PMID:24778419; http://dx.doi.org/10.1084/jem.20131916
14. Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity 2014; 40:642-56; PMID:24837101; http://dx.doi.org/10.1016/j.immuni.2014.04.016
15. Croncek I, Pathria P, Svinka J, Eferl R. Induction of colorectal cancer in mice and histomorphometric evaluation of tumors. Methods Mol Biol 2015; 1267:145-64; PMID:25636468; http://dx.doi.org/10.1007/978-1-4939-2297-0_7
16. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, den Hoff MJ, Moorman AF. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res 2009; 37:e45; PMID:19237396; http://dx.doi.org/10.1093/nar/gkp045
17. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4:44-57; PMID:19131956; http://dx.doi.org/10.1038/nprot.2008.211
18. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37:1-13; PMID:1903363; http://dx.doi.org/10.1093/nar/gkn923
19. Latchman Y, Wood C, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long A, Brown J, Nunes R et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2 (3):261-8; PMID:11224527; http://dx.doi.org/10.1038/85330
20. Jakubzick C, Bognovic M, Bonito AJ, Kuan EL, Merad M, Randolph GJ. Lymph-migrating, tissue-derived dendritic cells are minor constituents within steady-state lymph nodes. J Exp Med 2008; 205:2839-50; PMID:18981237; http://dx.doi.org/10.1084/jem.20081430
21. Zhang R, Ito S, Nishio N, Cheng Z, Suzuki H, Isobe KI. Dextran sulfate sodium increases splenic Gr1(CD11b)CD11c(-) cells which accelerates recovery from colitis following intravenous transplantation. Clin Exp Immunol 2011; 164:417-27; PMID:21413942; http://dx.doi.org/10.1111/j.1365-2249.2011.04374.x
22. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml BU, ER U, Diamond MS et al. Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in...
Tolerance to Tissue-associated Antigens. J Exp Med 2002; 196:1099-104; PMID:12391021; http://dx.doi.org/10.1084/jem.20020861

39. Ganguly D, Haak S, Sirisak V, Reizis B. The role of dendritic cells in autoimmunity. Nat Rev Immunol 2013; 13:566-77; PMID:23827956; http://dx.doi.org/10.1038/nri3477

40. Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev 2010; 234(1):18-30; PMID:20193009; http://dx.doi.org/10.1111/j.1600-065X.2009.01055.x

41. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196:1091-7; PMID:12391020; http://dx.doi.org/10.1084/jem.20021215

42. Iyoda T, Shimoyama S, Liu K, Matsumoto A, Akiyama Y, Maeda Y, Taka-hara K, Steinman RM, Inaba K. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002; 195:1289-92; PMID:12021301; http://dx.doi.org/10.1084/jem.20020161

43. Clausen BE, Burkhardt C, Reith W, Renkawitz R, I F. Conditional genetic targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999; 8(4):265-77; PMID:10621974

44. Ehrenk JM, Sunderkotter C, Fodl D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009; 86:557-66; PMID:19451397; http://dx.doi.org/10.1187/jlb.1008647

45. Cheng P, Corzo CA, Luetteke N, Yu B, Nagarai S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49; PMID:18809714; http://dx.doi.org/10.1084/jem.20080132

46. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013

47. Xu D, Liu H, Komai-Koma M, Campbell C, McSharry L, Alexander J, Liew FY. CD4+CD25+ regulatory T cells suppress differentiation and functions of Th1 and Th2 cells. Leishmania major infection, and colitis in mice. J Immunol 2003; 170:394-9; PMID:12496424; http://dx.doi.org/10.1042/jim.20031307

48. Kristinsson SY, Gridley G, Hoover RN, Check D, Lanegren D. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. Haematologica 2014; 99:392-8; PMID:24056815; http://dx.doi.org/10.3324/haematol.2013.092460